{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:34Z","timestamp":1788502354794,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Merkel cell carcinoma (MCC) is an aggressive form of skin cancer with a high mortality rate and limited therapeutic options. Approximately 80% of MCC cases are associated with Merkel cell polyomavirus (MCPyV). The Large T antigen (LTAg) and Small T antigen (STAg) of MCPyV are persistently expressed in tumors and important for viral maintenance and oncogenic transformation of infected cells, making them attractive targets for therapeutic vaccination. Here, we describe the development and preclinical evaluation of DNA vaccines against MCPyV LTAg (LTAgvax) and STAg (STAgvax). Vaccines were designed based on highly conserved regions across MCPyV strains and demonstrated robust expression\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Immunization elicited strong antigen specific polyfunctional immune responses, including both CD4+ and CD8+ T cells producing IFN\u03b3, TNF\u03b1, and IL2. We observed CD8+ T cells with cytotoxic potential, evidenced by expression of T-bet and CD107a. Importantly, these immune responses were observed in inbred and outbred mouse models, suggesting broad immunogenicity across diverse genetic backgrounds, enhancing the translational relevance of both vaccines. In a minimal residual disease challenge, LTAgvax controlled growth of B16 tumors transduced to express LTAg in mice, improving survival of tumor bearing mice. In a therapeutic challenge, LTAgvax extensively remodeled the tumor microenvironment, with fewer immunosuppressive immune cells and enhanced CD4+ and CD8+ T cell infiltration. The intratumoral CD8+ T cells were more activated and a greater percentage of them had the effector memory phenotype suggesting greater capacity to fight the tumor. This led to improved survival of mice which was further enhanced when mice were co-treated with LTAgvax and anti-PD1 antibody. Together, these findings demonstrate that MCPyV T antigen targeting DNA vaccines induce robust, multifunctional immune responses and control tumor growth. Further development of these vaccines for immunotherapy of MCPyV+ MCC is warranted.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1840943","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:27Z","timestamp":1788499767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthetic consensus DNA vaccines against Merkel cell polyomavirus large and small T antigens induce robust polyfunctional T cell responses"],"prefix":"10.3389","volume":"17","author":[{"given":"Pratik S.","family":"Bhojnagarwala","sequence":"first","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Duperret","sequence":"additional","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspen","family":"Trautz","sequence":"additional","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010103","article-title":"Merkel cell carcinoma\u2014update on diagnosis, management and future perspectives","volume":"15","author":"Zaggana","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.028","article-title":"Merkel cell carcinoma: current US incidence and projected increases based on changing demographics","volume":"78","author":"Paulson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.028","article-title":"Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection","volume":"137","author":"Moshiri","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.131","article-title":"Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline","volume":"51","author":"Lebbe","year":"2015","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0002","article-title":"Merkel cell carcinoma, version 1.2024","volume":"22","author":"Schmults","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40425-018-0404-0","article-title":"Multidimensional, quantitative assessment of PD-1\/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab","volume":"6","author":"Giraldo","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-1513","article-title":"Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood","volume":"17","author":"Iyer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2017-ct074","article-title":"Non-comparative, open label, multiple cohort, phase 1\/2 study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma","volume":"77","author":"Topalian","year":"2017","journal-title":"Cancer Res (abstract)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000313","article-title":"Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program","volume":"8","author":"Walker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002646","article-title":"First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study","volume":"9","author":"D\u2019Angelo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B13","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial","volume":"8","author":"D\u2019Angelo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B14","volume-title":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics. Surveillance Research Program","year":"2025"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-011720-121757","article-title":"Molecular mechanisms of Merkel cell polyomavirus transformation and replication","volume":"7","author":"Liu","year":"2021","journal-title":"Annu Rev Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.008","article-title":"DNA-based immunotherapy for cancer: in vivo approaches for recalcitrant targets","volume":"33","author":"Bhojnagarwala","year":"2025","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.01.006","article-title":"DNA vaccines: prime time is now","volume":"65","author":"Gary","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-026-04302-5","article-title":"synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy","volume":"75","author":"Bhojnagarwala","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.10.078","article-title":"Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6\/E7 fusion antigen","volume":"27","author":"Yan","year":"2009","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.03.069","article-title":"Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6\/E7 fusion consensus protein in mice and rhesus macaques","volume":"26","author":"Yan","year":"2008","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1013","article-title":"A designer cross-reactive DNA immunotherapeutic vaccine that targets multiple MAGE-A family members simultaneously for cancer therapy","volume":"24","author":"Duperret","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7020044","article-title":"Novel synthetic DNA immunogens targeting latent expressed antigens of Epstein-Barr virus elicit potent cellular responses and inhibit tumor growth","volume":"2","author":"Wojtak","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.12.017","article-title":"DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas","volume":"24","author":"Zhu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.04.005","article-title":"A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation","volume":"21","author":"Bhojnagarwala","year":"2021","journal-title":"Mol Therapy-Oncolytis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010056","article-title":"Immune therapy targeting E6\/E7 oncogenes of human papillomavirus type 6 (HPV-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis","volume":"8","author":"Aggarwal","year":"2020","journal-title":"Vaccines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1987","article-title":"Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus\u2013associated recurrent\/metastatic head and neck squamous cell carcinoma","volume":"29","author":"Aggarwal","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B27","article-title":"INOVIO's VGX-3100 demonstrates positive phase 2 efficacy in treatment of precancerous anal dysplasia caused by HPV-16\/18","year":"2020"},{"key":"B28","article-title":"VGX-3100 and electroporation in treating patients with HIV-positive high-grade anal lesions","year":"2024","journal-title":"ClinicalTrials.gov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01216-13","article-title":"Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806526105","article-title":"T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus","volume":"105","author":"Shuda","year":"2008","journal-title":"PNAS"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human Merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000796","article-title":"NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence","volume":"2","author":"Nielsen","year":"2007","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.072","article-title":"Development of a DNA vaccine targeting Merkel cell polyomavirus","volume":"7","author":"Zeng","year":"2012","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-3-29","article-title":"Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen","volume":"3","author":"Gomez","year":"2013","journal-title":"Cell Bioscience"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1253568","article-title":"LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition","volume":"14","author":"Buchta Rosean","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01163-w","article-title":"Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial","volume":"7","author":"Garfinkle","year":"2026","journal-title":"Nat Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30475","article-title":"Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study","volume":"1238","author":"Paulson","year":"2017","journal-title":"Cancer"},{"key":"B40","article-title":"Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells","volume":"61","author":"Huber","year":"2001","journal-title":"Cancer Res"},{"key":"B41","article-title":"Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same","author":"Weiner","year":"2023"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:28Z","timestamp":1788499768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1840943"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1840943","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1840943"}}